Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia
6 affiliations
- 1Departamento de Oncología, Instituto Nacional de Cancerología
- 2Departamento de Cirugía de Tórax, Instituto Nacional de Cancerología y Fundación CTIC
- 3Departamento de Oncología, Clínica Universitaria Colombia, Fundación Universitaria Sanitas
- 4Departamento de Estadística, Instituto Nacional de Cancerología
- 5Departamento de Patología Oncologica, Instituto Nacional de Cancerología
- 6Instituto de Investigación, Universidad FUCS.
Abstract
Background: Evidence on the prognostic associations of programmed death-ligand 1 (PD-L1) and BRCA1-associated protein 1 (BAP1) in pleural mesothelioma (PM) remains inconsistent, and joint data from Latin American cohorts are limited. We evaluated these biomarkers in a Colombian cohort.
Methods: This retrospective single-center cohort included adults with histologically confirmed PM treated at the Instituto Nacional de Cancerología, Bogotá, from January 2011 through December 2023. PD-L1 was quantified using tumor proportion score (TPS), with ≥1% as the primary threshold; BAP1 was classified as retained or lost by nuclear immunoreactivity. Overall survival (OS) was measured from pathologic diagnosis to death. Event-free survival (EFS) was measured from diagnosis to first documented progression or death; patients without an event were censored at last contact. Kaplan–Meier methods and separate multivariable Cox models were used.
Results: Sixty-seven patients were included; 60/67 (89.6%) had locally advanced or metastatic disease. PD-L1 TPS ≥1% was present in 26/67 (38.8%), and BAP1 loss in 47/61 evaluable tumors (77.0%). All 67 patients died. Median OS was 9.20 months (95% CI, 6.11–14.13), and median EFS was 6.51 months (95% CI, 5.49–9.13). PD-L1 TPS ≥1% was not clearly associated with OS (adjusted HR, 1.03; 95% CI, 0.57–1.86) or EFS (adjusted HR, 1.11; 95% CI, 0.62–2.00). BAP1 loss also showed no clear adjusted association with OS (HR, 1.57; 95% CI, 0.78–3.16) or EFS (HR, 1.65; 95% CI, 0.82–3.33).
Conclusions: Neither PD-L1 TPS ≥1% nor BAP1 loss showed a clear adjusted association with survival. These jointly measured estimates extend the evidence from an underrepresented Latin American population but require external validation; the exploratory ≥5% and ≥10% analyses were based on only 14 and 7 patients, respectively.
Related
- Prognostic Significance of B7-H3, TROP2, and p16 Expression in Pleural Mesothelioma: Clinicopathological Correlations and Survival Outcomes
- Comparative and Histology-Aware Bioinformatic Characterization of FAM171A1 and FAM171A2 in Sarcoma: Expression, Prognostic, and Immune Associations
- The Prognostic Role of Vimentin Expression in Triple‐Negative Breast Cancer: A Retrospective Cohort Study
- PD-L1 Expression and Clinicopathologic Associations in Mediastinal Aggressive Large B-Cell Lymphomas: A Retrospective Single-Center Study
- Prognostic value of Gli1 expression on colorectal cancer: a retrospective study.
BibTeX
@article{bruges2026prognostic,
title = {{Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia}},
author = {Ricardo Brugés and Carlos Carvajal and Angela Luna-Meza and Marcela Núñez and Alejandra Navarrete and Rafael Parra-Medina},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1920798},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1920798/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia
AU - Ricardo Brugés
AU - Carlos Carvajal
AU - Angela Luna-Meza
AU - Marcela Núñez
AU - Alejandra Navarrete
AU - Rafael Parra-Medina
PY - 2026
DA - 2026/10/14
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1920798
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1920798/full
AB - Background: Evidence on the prognostic associations of programmed death-ligand 1 (PD-L1) and BRCA1-associated protein 1 (BAP1) in pleural mesothelioma (PM) remains inconsistent, and joint data from Latin American cohorts are limited. We evaluated these biomarkers in a Colombian cohort. Methods: This retrospective single-center cohort included adults with histologically confirmed PM treated at the Instituto Nacional de Cancerología, Bogotá, from January 2011 through December 2023. PD-L1 was quantified using tumor proportion score (TPS), with ≥1% as the primary threshold; BAP1 was classified as retained or lost by nuclear immunoreactivity. Overall survival (OS) was measured from pathologic diagnosis to death. Event-free survival (EFS) was measured from diagnosis to first documented progression or death; patients without an event were censored at last contact. Kaplan–Meier methods and separate multivariable Cox models were used. Results: Sixty-seven patients were included; 60/67 (89.6%) had locally advanced or metastatic disease. PD-L1 TPS ≥1% was present in 26/67 (38.8%), and BAP1 loss in 47/61 evaluable tumors (77.0%). All 67 patients died. Median OS was 9.20 months (95% CI, 6.11–14.13), and median EFS was 6.51 months (95% CI, 5.49–9.13). PD-L1 TPS ≥1% was not clearly associated with OS (adjusted HR, 1.03; 95% CI, 0.57–1.86) or EFS (adjusted HR, 1.11; 95% CI, 0.62–2.00). BAP1 loss also showed no clear adjusted association with OS (HR, 1.57; 95% CI, 0.78–3.16) or EFS (HR, 1.65; 95% CI, 0.82–3.33). Conclusions: Neither PD-L1 TPS ≥1% nor BAP1 loss showed a clear adjusted association with survival. These jointly measured estimates extend the evidence from an underrepresented Latin American population but require external validation; the exploratory ≥5% and ≥10% analyses were based on only 14 and 7 patients, respectively.
SN - 2234-943X
ER -